MEK inhibitor

systematic review meta-analysis network meta-analysis

Select melanoma All type of patient       combined BRAF and MEK inhibitioncombined BRAF-MEK inhibitorsMEK1/2 inhibitor encorafenib plus binimetinibselumetinibtrametinib + dabrafenib vemurafenib and cobimetinib vs 1L unresectablevs placebo or control      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (6)death (overall survival) (3)aaa (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
melanoma
encorafenib plus binimetinib
COLUMBUS, 2018      NCT	encorafenib plus binimetinib	vemurafenib	1L		Risk of bias	suggesting
selumetinib
Kirkwood, 2012	selumetinib	temozolomide				-
Kirkwood	selumetinib	temozolomide				-
trametinib + dabrafenib
Flaherty, 2012      NCT	trametinib and dabrafenib	dabrafenib				suggesting
COMBI-D (Long), 2014        NCT	trametinib and dabrafenib	dabrafenib	1L unresectable			suggesting
COMBI-AD, 2017      NCT	trametinib and dabrafenib	placebo	adjuvant		Low risk of bias	suggesting
COMBI neo, 2018      NCT	trametinib and dabrafenib	SOC	adjuvant			-
COMBI-V (Robert), 2015      NCT	trametinib and dabrafenib	vemurafenib	1L			suggesting
vemurafenib and cobimetinib
Larkin, 2014      NCT	vemurafenib and cobimetinib	vemurafenib				suggesting